Pliant Therapeutics, Inc. PLRX
We take great care to ensure that the data presented and summarized in this overview for PLIANT THERAPEUTICS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PLRX
View all-
Deep Track Capital, LP Greenwich, CT5.75MShares$73.2 Million2.83% of portfolio
-
Black Rock Inc. New York, NY4.66MShares$59.3 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.96MShares$50.4 Million0.01% of portfolio
-
First Light Asset Management, LLC Edina, MN3.53MShares$45 Million4.12% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.48MShares$44.3 Million0.0% of portfolio
-
Laurion Capital Management LP New York, NY3.47MShares$44.2 Million0.45% of portfolio
-
Redmile Group, LLC San Francisco, CA3.1MShares$39.4 Million1.82% of portfolio
-
Chi Advisors LLC New York, NY3.01MShares$38.4 Million25.76% of portfolio
-
Blue Owl Capital Holdings LP New York, NY3MShares$38.2 Million11.86% of portfolio
-
Trv Gp Iv, LLC Boston, MA2.13MShares$27.2 Million15.4% of portfolio
Latest Institutional Activity in PLRX
Top Purchases
Top Sells
About PLRX
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Insider Transactions at PLRX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 02
2024
|
Keith Lamont Cummings Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,000
+7.17%
|
$42,000
$2.08 P/Share
|
|
Jan 23
2024
|
Bernard Coulie President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
128,150
+22.38%
|
-
|
|
Jan 23
2024
|
Lily Cheung Chief Human Resource Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,000
+49.25%
|
-
|
|
Jan 23
2024
|
Keith Lamont Cummings Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
55,250
+18.11%
|
-
|
|
Jan 23
2024
|
Mike Ouimette General Counsel & Corp. Sec'y |
BUY
Grant, award, or other acquisition
|
Direct |
31,500
+26.64%
|
-
|
|
Jan 23
2024
|
Hans Hull Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,500
+12.7%
|
-
|
|
Jan 23
2024
|
Eric Lefebvre Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
42,900
+17.67%
|
-
|
|
Jan 17
2024
|
Keith Lamont Cummings Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
9,781
-4.79%
|
$166,277
$17.23 P/Share
|
|
Jan 17
2024
|
Eric Lefebvre Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,295
-6.16%
|
$175,015
$17.23 P/Share
|
|
Jan 17
2024
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
25,721
-7.52%
|
$437,257
$17.23 P/Share
|
|
Jan 17
2024
|
Hans Hull Chief Business Officer |
SELL
Open market or private sale
|
Direct |
9,786
-5.02%
|
$166,362
$17.23 P/Share
|
|
Jan 17
2024
|
Mike Ouimette General Counsel & Corp. Sec'y |
SELL
Open market or private sale
|
Direct |
5,197
-8.6%
|
$88,349
$17.23 P/Share
|
|
Aug 04
2023
|
Hans Hull Chief Business Officer |
SELL
Open market or private sale
|
Direct |
20,050
-9.33%
|
$401,000
$20.01 P/Share
|
|
Aug 04
2023
|
Hans Hull Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,791
+3.93%
|
$17,582
$2.08 P/Share
|
|
Aug 03
2023
|
Hans Hull Chief Business Officer |
BUY
Open market or private sale
|
Direct |
1,800
+0.87%
|
$36,000
$20.0 P/Share
|
|
Aug 03
2023
|
Hans Hull Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,800
+0.86%
|
$3,600
$2.08 P/Share
|
|
Aug 03
2023
|
Hans Hull Chief Business Officer |
SELL
Open market or private sale
|
Direct |
13,069
-5.96%
|
$261,380
$20.0 P/Share
|
|
Jul 20
2023
|
Mike Ouimette General Counsel & Corp. Sec'y |
SELL
Open market or private sale
|
Direct |
4,755
-7.29%
|
$80,835
$17.55 P/Share
|
|
Jul 17
2023
|
Mike Ouimette General Counsel & Corp. Sec'y |
SELL
Open market or private sale
|
Direct |
12,778
-16.39%
|
$230,004
$18.01 P/Share
|
|
Jul 17
2023
|
Hans Hull Chief Business Officer |
SELL
Open market or private sale
|
Direct |
17,937
-7.56%
|
$322,866
$18.01 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 598K shares |
|---|---|
| Exercise of conversion of derivative security | 68.1K shares |
| Open market or private sale | 1.8K shares |
| Open market or private sale | 242K shares |
|---|